Is Slynd (drospirenone) indicated for the treatment of endometriosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Slynd is NOT FDA-Approved for Endometriosis

Slynd (drospirenone 4 mg) is FDA-indicated solely for contraception in females of reproductive potential, not for the treatment of endometriosis 1. However, emerging evidence suggests it may be effective for managing endometriosis-associated symptoms as an off-label use.

FDA-Approved Indication

The FDA label clearly states that Slynd's only indication is "for use by females of reproductive potential to prevent pregnancy" 1. There is no mention of endometriosis treatment in the approved indications.

Off-Label Use: Supporting Evidence

While not FDA-approved for endometriosis, clinical data supports its potential efficacy:

Adolescent Population Data

  • In a retrospective study of 61 adolescents with endometriosis (97% laparoscopically confirmed), 67% reported less pain at follow-up when treated with continuous drospirenone 2
  • 52% achieved absence of bleeding/spotting 2
  • The medication was well-tolerated, with only 25% discontinuing (most commonly due to breakthrough bleeding) 2
  • Another study of 136 adolescents showed 84.6% of dysmenorrhea patients and 77.8% of pelvic pain patients reported resolution or improvement 3

Combination Formulations (Different from Slynd)

The evidence base is stronger for combined oral contraceptives containing drospirenone with ethinyl estradiol, which are FDA-approved for acne but used off-label for endometriosis 4:

  • ACOG guidelines (2000) recommend oral contraceptives as effective for endometriosis pain relief (Level B evidence) 4
  • Multiple studies demonstrate efficacy of drospirenone/ethinyl estradiol combinations for endometriosis-associated pain 5, 6, 7

Clinical Considerations

When to Consider Slynd for Endometriosis (Off-Label)

  • Patients with contraindications to estrogen (this is where Slynd has particular advantage) 2
  • Adolescents and young adults with laparoscopically-confirmed endometriosis
  • Patients who have failed other progestin-only options (norethindrone, norethindrone acetate)

Key Monitoring Requirements

Before initiating:

  • Check serum potassium in patients on medications that increase potassium or those with risk factors for hyperkalemia 1
  • Assess for contraindications: renal impairment, adrenal insufficiency, hepatic impairment 1

During treatment:

  • Monitor for breakthrough bleeding (occurs in 64.4% at cycle 1, decreasing to 40.3% by cycle 13) 1
  • Reassess potassium during first treatment cycle if at risk 1
  • Evaluate persistent bleeding for pregnancy or malignancy 1

Common Pitfalls

  • Do not use in patients with renal impairment - this is an absolute contraindication due to hyperkalemia risk 1
  • Expect significant breakthrough bleeding initially; counsel patients that this typically improves over 3-6 months 1, 3
  • Unlike combined oral contraceptives, Slynd requires 7 days of backup contraception if started >1 day after menses 8

Bottom Line

Use Slynd for endometriosis only as off-label therapy, particularly when estrogen-containing contraceptives are contraindicated. The strongest evidence supports combined drospirenone/ethinyl estradiol formulations for endometriosis pain 4, but emerging data suggests progestin-only drospirenone (Slynd) may be effective, especially in adolescents 2, 3. Screen carefully for hyperkalemia risk factors before prescribing, and counsel patients about expected breakthrough bleeding that typically improves over time.

References

Research

Use of the Drospirenone-Only Contraceptive Pill in Adolescents with Endometriosis.

Journal of pediatric and adolescent gynecology, 2024

Research

Use of Continuous Oral Drospirenone for Menstrual Suppression in Adolescents.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2025

Research

Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2016

Research

A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012

Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Related Questions

In a female patient with mast cell activation syndrome (MCAS) and endometriosis who has significant cold intolerance and is taking drospirenone 4 mg daily for contraception without improvement in pain or MCAS symptoms, should oral micronized progesterone (OMP) be added, or would switching to a different hormone regimen such as micronized progesterone (Simo) be more appropriate?
In a patient with endometriosis and mast cell activation syndrome who is currently taking the progestin‑only pill drospirenone 4 mg (Slynd) and not on combined hormonal therapy, should oral micronized progesterone be added or substituted, and what are the recommended next steps for pain management?
In a reproductive‑age woman taking Slynd (drospirenone‑only oral contraceptive) for dysmenorrhea who developed facial, chest, and back acne after 5–6 months, does the medication improve acne?
What is the best treatment for endometriosis, and does the drospirenone‑only pill (Slynd) work?
Is Yasmin (drospirenone/ethinyl estradiol) an appropriate oral contraceptive for a woman with adenomyosis or uterine fibroids?
Are there any drug interactions between betahistine (Betasert) and losartan, rivaroxaban, valsartan (Concord), and tamsulosin (Tamsol)?
Which blood tests should be ordered for a 12-year-old patient with Pitt-Hopkins syndrome and low ferritin?
What are the differential diagnoses for vomiting in a child with a ventriculoperitoneal (VP) shunt?
What is the recommended diagnostic workup and management for a patient with Multiple Endocrine Neoplasia type 1 (MEN1)?
What is the recommended management for a patient with chronic immune thrombocytopenia (ITP) persisting longer than 12 months?
What is the appropriate iron supplementation and management for a 12‑year‑old child with autism who has iron deficiency (ferritin 9 ng/mL, hemoglobin 11.7 g/dL, hematocrit 34.9 %, red blood cell count 3.7 ×10⁶/µL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.